Description Emistat is a selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with anti-emetic activity.
Indications Emistat®is indicated for the prevention and treatment of post-operative nausea and vomiting, and for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.
Supply Emistat®4mg Tablet: Each box contains 3x10 tablets in blister pack. Emistat®8mg Tablet: Each box contains 3x10 tablets in blister pack. Emistat®4ml Injection: Each box contains 2x5s ampoules in blister pack Emistat®oral solution: Each pack contains 50 ml oral solution in PET bottle with 5 ml spoon and 1.25 ml dropper.
